Skip to main content
Nature Portfolio logoLink to Nature Portfolio
. 2024 Mar 11;30(5):1500. doi: 10.1038/s41591-024-02910-1

Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

Lindsay B Kilburn 1,, Dong-Anh Khuong-Quang 2, Jordan R Hansford 3,4, Daniel Landi 5, Jasper van der Lugt 6, Sarah E S Leary 7, Pablo Hernáiz Driever 8, Simon Bailey 9, Sébastien Perreault 10, Geoffrey McCowage 11, Angela J Waanders 12, David S Ziegler 13,14,15, Olaf Witt 16,17,18,19,20, Patricia A Baxter 21, Hyoung Jin Kang 22, Timothy E Hassall 23, Jung Woo Han 24, Darren Hargrave 25, Andrea T Franson 26, Michal Yalon Oren 27, Helen Toledano 28, Valérie Larouche 29, Cassie Kline 30, Mohamed S Abdelbaki 31, Nada Jabado 32, Nicholas G Gottardo 33, Nicolas U Gerber 34, Nicholas S Whipple 35, Devorah Segal 36, Susan N Chi 37, Liat Oren 38, Enrica E K Tan 39, Sabine Mueller 40, Izzy Cornelio 41, Lisa McLeod 41, Xin Zhao 41, Ashley Walter 41, Daniel Da Costa 41, Peter Manley 41, Samuel C Blackman 41, Roger J Packer 42, Karsten Nysom 43
PMCID: PMC11108768  PMID: 38467878

Correction to: Nature Medicine 10.1038/s41591-023-02668-y, published online 17 November 2023.

In the version of the article initially published, in the third paragraph of the “RAPNO criteria (secondary endpoints)” section, the text now reading “Thirteen (17.1%) patients initially had a best overall response of PD…” originally read “Thirty-one patients initially had PD…”. This has been corrected in the HTML and PDF versions of the article.


Articles from Nature Medicine are provided here courtesy of Nature Publishing Group

RESOURCES